Bivalirudin infusion to reduce ventricular infarction: the open-label, randomised Bivalirudin Infusion for Ventricular InfArction Limitation (BIVAL) study

EuroIntervention 2017;13:e540-e548 published online ahead of print May 2017 published online e-edition August 2017. DOI: 10.4244/EIJ-D-17-00307

Robert-Jan van Geuns
Robert Jan van Geuns1*, MD, PhD; Georgios Sideris2, MD, PhD; Niels Van Royen3, MD, PhD; Rami El Mahmoud4, MD; Roberto Diletti1, MD, PhD; Claire Bal dit Sollier2, PhD; Jerome Garot5, MD, PhD; Nina W. Van Der Hoeven3, MD, PhD; Bernardo Cortese6, MD; Li Ding7, PhD; Ilknur Lechthaler8; Efthymios N. Deliargyris9, MD; Prodromos Anthopoulos8, MD; Ludovic Drouet2, MD, PhD
1. Erasmus MC, Rotterdam, the Netherlands; 2. Hôpital AP-HP Lariboisière, Paris, France; 3. Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; 4. Hôpital Ambroise Paré, Boulogne, France; 5. Hôpital Privé Jacques Cartier, Ramsay Générale de Santé, I

Aims: The aim of the study was to investigate whether bivalirudin versus unfractionated heparin (UFH) reduces infarct size (IS) for primary percutaneous coronary intervention (PPCI) in la

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

adjunctive pharmacologyclinical trialsmagnetic resonance imaging (mri)other imaging modalitiesst-elevation myocardial infarction (stemi)
Coronary interventionsSTEMIAdjunctive pharmacotherapy
Read next article
Comparison of a new slender 6 Fr sheath with a standard 5 Fr sheath for transradial coronary angiography and intervention: RAP and BEAT (Radial Artery Patency and Bleeding, Efficacy, Adverse evenT), a randomised multicentre trial

Latest news